Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)

University of Bologna5 sites in 3 countries10,000 target enrollmentMay 1, 2025

ConditionsCancer Related Cardiovascular Toxicity

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cancer Related Cardiovascular Toxicity
Sponsor: University of Bologna
Enrollment: 10000
Locations: 5
Primary Endpoint: All causes mortality
Status: Recruiting
Last Updated: 10 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction

Registry

clinicaltrials.gov

Start Date

May 1, 2025

End Date

December 31, 2026

Last Updated

10 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Bologna

Responsible Party

Principal Investigator

Olivia Manfrini, MD

Professor

University of Bologna

Eligibility Criteria

Inclusion Criteria

•Age 18 years old or older
•Capable of giving informed consent
•Diagnosis of cancer scheduled for treatment according to treating physician's discretion
•Life expectancy \>1 year
•For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs

Exclusion Criteria

•Age \<18 years old
•Not able to give informed consent
•Life expectancy \<1 year
•Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's